Overview

Study of Vortioxetine (Lu AA21004) in Major Depressive Disorder in Asian Countries

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study will be conducted with the aim of investigating the efficacy, safety and tolerability of 10 mg/day Vortioxetine in Asian patients compared to an approved active comparator (venlafaxine extended release 150 mg/day).
Phase:
Phase 3
Details
Lead Sponsor:
H. Lundbeck A/S
Treatments:
Venlafaxine Hydrochloride
Vortioxetine